GT Biopharma Inc GTBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
-
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
-
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
-
GT Biopharma Reports Second Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $5.32
- Day Range
- $5.11–5.40
- 52-Week Range
- $4.91–28.75
- Bid/Ask
- $5.00 / $5.28
- Shares Outstanding
- 2.06M
- Market Cap
- $9.26M
- Volume/Avg
- 33,417 / 63,762
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1
- Website
- https://www.gtbiopharma.com
Valuation
|
Metric
|
GTBP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.64 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
GTBP
Financial Strength
|
Metric
|
GTBP
|
|---|---|
Quick Ratio | 2.24 |
Current Ratio | 2.61 |
Interest Coverage | −61.63 |
Quick Ratio
GTBP
Profitability
|
Metric
|
GTBP
|
|---|---|
Return on Assets (Normalized) | −63.44% |
Return on Equity (Normalized) | −98.35% |
Return on Invested Capital (Normalized) | −88.98% |
Return on Assets
GTBP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@>^?NB | LOCK|L@lB | $142B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|J?#?D$$ | LOCK|t<#Y | $96B | |||
| Moderna Inc
MRNA
| LOCK|y@Zh^b | LOCK|@Vb | $89B | |||
| argenx SE ADR
ARGX
| LOCK|T%VvTW | LOCK|c& | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?#nN?K | LOCK|KM | $43B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|N@<$<Gp | LOCK|S$fG? | $30B | |||
| Incyte Corp
INCY
| LOCK|?#@d@@ | LOCK|<? | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|?Qb&W&@ | LOCK|h@ | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|B>sKr@^ | LOCK|Vz!C> | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|^#n%><l | LOCK|?v | $15B |
United States